1. Search Result
Search Result
Results for "

MDM-2/p53

" in MedChemExpress (MCE) Product Catalog:

72

Inhibitors & Agonists

2

Screening Libraries

4

Peptides

2

Recombinant Proteins

3

Isotope-Labeled Compounds

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-70027A

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    p53 and MDM2 proteins-interaction-inhibitor dihydrochloride is an inhibitor of the interaction between p53 and MDM2 proteins.
    <em>p53</em> and <em>MDM2</em> proteins-interaction-inhibitor dihydrochloride
  • HY-70027

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    p53 and MDM2 proteins-interaction-inhibitor (chiral) (Compound 32) is an inhibitor of the interaction between p53 and MDM2 proteins.
    <em>p53</em> and <em>MDM2</em> proteins-interaction-inhibitor (chiral)
  • HY-148833

    MDM-2/p53 Cancer
    MDM2-p53-IN-16 is a MDM2-p53 complex inhibitor with an IC50 value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research .
    <em>MDM2</em>-<em>p53</em>-IN-16
  • HY-70028

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    p53 and MDM2 proteins-interaction-inhibitor (racemic) (Compound 2j) is an inhibitor of the interaction between p53 and MDM2 proteins.
    <em>p53</em> and <em>MDM2</em> proteins-interaction-inhibitor (racemic)
  • HY-151172

    MDM-2/p53 Apoptosis Cancer
    MDM2-p53-IN-15 is a MDM2-p53 inhibitor with an IC50 value of 26.1 nM. MDM2-p53-IN-15 inhibits the proliferation of various cancer cells and induces cell apoptosis. MDM2-p53-IN-15 can be used for the research of cancer .
    <em>MDM2</em>-<em>p53</em>-IN-15
  • HY-W340839

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    p53-MDM2-IN-1 (Example 30) is an inhibitor of p53-MDM2/X protein interaction with an Ki value of 23.35 µM. p53-MDM2-IN-1 can be used for anti-tumor research .
    <em>p53</em>-<em>MDM2</em>-IN-1
  • HY-116052

    MDM-2/p53 NF-κB Cancer
    p53-MDM2-IN-2 (Compound 5q) is an orally active p53-MDM2 inhibitor with a Ki value of 0.25 μM. p53-MDM2-IN-2 exerts antitumor activity by inhibiting NF-κB pathway .
    <em>p53</em>-<em>MDM2</em>-IN-<em>2</em>
  • HY-121893

    MDM-2/p53 NF-κB Cancer
    p53-MDM2-IN-3 (Compound 5s) is an orally active p53-MDM2 inhibitor with a Ki value of 0.25 μM. p53-MDM2-IN-3 exerts antitumor activity by inhibiting NF-κB pathway .
    <em>p53</em>-<em>MDM2</em>-IN-3
  • HY-161039

    MDM-2/p53 Cancer
    MDM2-p53-IN-18 (Compd A-7b) is a MDM2-p53 interaction inhibitor .
    <em>MDM2</em>-<em>p53</em>-IN-18
  • HY-151171

    MDM-2/p53 Cancer
    MDM2/4-p53-IN-3 is a MDM2/4-p53 protein-protein interactions (PPIs) inhibitor (IC50s: 18.5 nM for MDM2-p53, 14.8 nM for MDM4-p53). MDM2/4-p53-IN-3 can be used in the research of cancers, such as colon cancer .
    <em>MDM2</em>/4-<em>p53</em>-IN-3
  • HY-151169

    MDM-2/p53 Cancer
    MDM2/4-p53-IN-1 is a potent MDM2-p53 and MDM4-p53 inhibitor with IC50 values of 35.9, 57.4 nM, respectively. MDM2/4-p53-IN-1 shows antiproliferative activity .
    <em>MDM2</em>/4-<em>p53</em>-IN-1
  • HY-161041

    MDM-2/p53 Cancer
    MDM2-p53-IN-20 (Compd B-11j) is a synthetic MDM2-p53 interaction inhibitor that play an important role in cancer .
    <em>MDM2</em>-<em>p53</em>-IN-20
  • HY-151170

    MDM-2/p53 Apoptosis Cancer
    MDM2/4-p53-IN-2 (2q) is a potent dual MDM2/ MDM4 inhibitor and p53 activator with the IC50 values of 70.7 nM for MDM2- p53 and 81.4 nM for MDM4-p53 complexes. MDM2/4-p53-IN-2 regulates the cell cycle, induces cell apoptosis and has anticancer activity .
    <em>MDM2</em>/4-<em>p53</em>-IN-<em>2</em>
  • HY-161040

    Others Cancer
    MDM2-p53-IN-19 (Compound A-8d) is a chemical intermediate that can be used to synthesize inhibitors of the MDM2-p53 interaction with anticancer activity .
    <em>MDM2</em>-<em>p53</em>-IN-19
  • HY-162247

    MDM-2/p53 Cancer
    MDM2-IN-26 (compound A3) is an MDM2 inhibitor that can activate the tumor suppressor function of p53 by blocking the interaction between MDM2 and p53 (MDM2 is the main negative regulator of p53). MDM2-IN-26 can be used for cancer research .
    MDM2-IN-26
  • HY-P4210

    ALRN-6924; MP-4897

    MDM-2/p53 Cancer
    Sulanemadlin (ALRN-6924) is a potent and cell-permeating p53-based peptidomimetic macrocycles. Sulanemadlin is a inhibitor of the p53-MDM2, p53-MDMX, or both p53 and MDM2 and MDMX protein-protein interactions. Sulanemadlin can be used for cancers research .
    Sulanemadlin
  • HY-14967

    MDM-2/p53 Cancer
    NSC 66811 is a MDM2-p53 inhibitor, with a Ki of 120 nM for binding to MDM2 .
    NSC 66811
  • HY-123544

    MDM-2/p53 Cancer
    RDR03871 (compound 2) is a potent dual MDM2/MDM4 inhibitor with IC50 values of 35.4 nM and 10.4 nM for MDM2-p53 and MDM4-p53, respectively .
    RDR03871
  • HY-155974

    MDM-2/p53 Cancer
    MeOIstPyrd is an anti-skin cancer agent. MeOIstPyrd inhibits cell proliferation, migration, and spheroid formation by activating the mitochondrial intrinsic apoptotic pathway. MeOIstPyrd induces DNA damage. MeOIstPyrd activates p53, and increases the half-life of p53 and stabilizes p53 by phosphorylating it at ser15. MeOIstPyrd binds to MDM2 in the p53 sub-pocket and blocks p53-MDM2 interaction .
    MeOIstPyrd
  • HY-149250

    MDM-2/p53 Apoptosis Cancer
    MDMX/MDM2-IN-2 is a potent p53-MDM2/MDMX dual inhibitors with Kis of 0.23 μM and 2.45 μM for MDM2 and MDMX, respectively. MDMX/MDM2-IN-2 inhibits the binding of p53 and MDM2 proteins. MDMX/MDM2-IN-2 restores the function of p53 and enables cell cycle arrest and apoptosis. MDMX/MDM2-IN-2 inhibits cell migration and invasion. MDMX/MDM2-IN-2 has antitumor activity .
    MDMX/MDM2-IN-2
  • HY-120086

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    RO-5963 is a dual p53-MDM2 and p53-MDMX inhibitor with IC50s of ~17 nM and ~24 nM, respectively .
    RO-5963
  • HY-130684

    MDM-2/p53 Cancer
    MDM2-IN-1 (Compound 30) is a synthetic MDM2-p53 interaction (MDM2) inhibitor and contains the trans (D-)configuration .
    MDM2-IN-1
  • HY-15676
    Idasanutlin
    30+ Cited Publications

    RG7388

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    Idasanutlin (RG7388) is a potent and selective MDM2 antagonist, inhibiting p53-MDM2 binding, with an IC50 of 6 nM.
    Idasanutlin
  • HY-50696
    Nutlin-3
    15+ Cited Publications

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    Nutlin-3 is a commercial available p53-MDM2 inhibitor, with Ki of 90 nM.
    Nutlin-3
  • HY-144105

    MDM-2/p53 Cancer
    NSC405640 is a potent inhibitor of the MDM2-p53 interaction. NSC405640 rescues structural p53 mutations. NSC405640 selectively inhibits the growth of cell lines with wild-type p53 .
    NSC405640
  • HY-101518

    APG-115; AA-115

    MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    Alrizomadlin (APG-115) is an orally active MDM2 protein inhibitor binding to MDM2 protein with IC50 and Ki values of 3.8 nM and 1 nM, respectively . Alrizomadlin blocks the interaction of MDM2 and p53 and induces cell-cycle arrest and apoptosis in a p53-dependent manner [2] .
    Alrizomadlin
  • HY-150620

    MDM-2/p53 Cancer
    BI-0282 (Compound 1) is a potent MDM2-p53 interaction inhibitor .
    BI-0282
  • HY-18052

    MDM-2/p53 Cancer
    AM-8553 is a MDM2/p53 inhibitor (KD: 0.4 nM for MDM2). AM-8553 has anti-tumor activity
    AM-8553
  • HY-18658
    Siremadlin
    4 Publications Verification

    NVP-HDM201; HDM201

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    Siremadlin (NVP-HDM201) is a potent, orally bioavailable and highly specific p53-MDM2 interaction inhibitor.
    Siremadlin
  • HY-149988

    MDM-2/p53 Cancer
    UNP-6457 is a potent active MDM2-p53 interaction inhibitor with an IC50 values of 8.9 nM .
    UNP-6457
  • HY-10959
    RG7112
    10+ Cited Publications

    RO5045337

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    RG7112 is a potent, selective, first clinical, orally active and blood-brain barrier crossed MDM2-p53 inhibitor, with an IC50 of 18 nM and a KD of 11 nM for binding to MDM2 .
    RG7112
  • HY-12296
    Navtemadlin
    10+ Cited Publications

    AMG 232; KRT-232

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of p53-MDM2 interaction, with an IC50 of 0.6 nM. Navtemadlin binds to MDM2 with a Kd of 0.045 nM [2].
    Navtemadlin
  • HY-123950

    MDM-2/p53 Apoptosis Cancer
    MMRi64 disrupts Mdm2-MdmX interactions. MMRi64 downregulates Mdm2 and MdmX in leukemia cells. MMRi64 induces p53 accumulation, and induces the apoptotic arm of the p53 pathway in leukemia/lymphoma cells. MMRi64 can be used for cancer research .
    MMRi64
  • HY-15676A

    RG7388 (enantiomer)

    Others Cancer
    Idasanutlin enantiomer is the isomer of Idasanutlin (HY-15676), and can be used as an experimental control. Idasanutlin (RG7388) is a potent and selective MDM2 antagonist, inhibiting p53-MDM2 binding, with an IC50 of 6 nM.
    Idasanutlin (enantiomer)
  • HY-125858
    MI-1061
    1 Publications Verification

    MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .
    MI-1061
  • HY-19726
    NSC59984
    1 Publications Verification

    MDM-2/p53 Cancer
    NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway . NSC59984 acts by targeting GOF-mutant p53 and stimulates p73 to restore the p53 pathway signaling [2].
    NSC59984
  • HY-125858A
    MI-1061 TFA
    1 Publications Verification

    MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    MI-1061 TFA is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 TFA potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .
    MI-1061 TFA
  • HY-12287
    YH239-EE
    1 Publications Verification

    MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent.
    YH239-EE
  • HY-17493
    MI-773
    4 Publications Verification

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    MI-773 is a potent MDM2-p53 protein‐protein interaction (PPI) inhibitor with high binding affinity against MDM2 (Kd=8.2 nM). MI-773 has antitumor activity [2].
    MI-773
  • HY-15335

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    Nutlin-3b is a p53/MDM2 inhibitor with an IC50 of 13.6 μM. Nutlin-3b is 150 times less potent in binding to MDM2 than Nutlin-3a .
    Nutlin-3b
  • HY-10029
    Nutlin-3a
    Maximum Cited Publications
    34 Publications Verification

    Rebemadlin

    MDM-2/p53 E1/E2/E3 Enzyme Autophagy Apoptosis Cancer
    Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC50=90 nM). Nutlin-3a inhibits MDM2-p53 interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53 wild-type ovarian carcinomas [2].
    Nutlin-3a
  • HY-10029A

    (Rac)-Rebemadlin

    MDM-2/p53 Autophagy Apoptosis E1/E2/E3 Enzyme Cancer
    (Rac)-Nutlin-3 (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC50=90 nM). (Rac)-Nutlin-3 inhibits MDM2-p53 interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. (Rac)-Nutlin-3 has the potential for the study of TP53 wild-type ovarian carcinomas [2].
    (Rac)-Nutlin-3
  • HY-12296S

    AMG 232-d7; KRT-232-d7

    Isotope-Labeled Compounds MDM-2/p53 E1/E2/E3 Enzyme Cancer
    Navtemadlin-d7 is the deuterium labeled Navtemadlin. Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of p53-MDM2 interaction, with an IC50 of 0.6 nM. Navtemadlin binds to MDM2 with a Kd of 0.045 nM[1][2].
    Navtemadlin-d7
  • HY-100765

    BI-0252 is an orally active, selective MDM2-p53 inhibitor with an IC50 of 4 nM. BI-0252 can induce tumor regressions in all animals of a mouse SJSA-1 xenograft, with concomitant induction of the tumor protein p53 (TP53) target genes and markers of apoptosis .
    BI-0252
  • HY-155571

    MDM-2/p53 IAP Cancer
    MDM2/XIAP-IN-3 (compound 3e) is a dual MDM2/XIAP inhibitor. MDM2/XIAP-IN-3 reduces MDM2 and XIAP protein levels and increases p53 expression, thereby inhibiting cancer cell growth and causing cell death .
    MDM2/XIAP-IN-3
  • HY-18986

    MI-77301

    MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective MDM2-p53 interaction inhibitor. SAR405838 binds to MDM2 with a Ki of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity [2].
    SAR405838
  • HY-13423
    Tenovin-1
    3 Publications Verification

    MDM-2/p53 Dihydroorotate Dehydrogenase Sirtuin Autophagy Cancer
    Tenovin-1, a p53 activator, protects p53 from MDM2-mediated degradation. Tenovin-1 acts through inhibition of the protein-deacetylating activities of SirT1 and SirT2. Tenovin-1 is also a dihydroorotate dehydrogenase (DHODH) inhibitor [2].
    Tenovin-1
  • HY-12941

    AM-7209 is a potent and selective MDM2-p53 interaction inhibitor with a Kd of 38 pM. AM-7209 inhibits the MDM2 amplified SJSA-1 osteosarcoma cell line with an IC50 of 1.6 nM. AM-7209 shows antitumor activities .
    AM-7209
  • HY-152859

    BI 907828

    E1/E2/E3 Enzyme MDM-2/p53 Cancer
    Brigimadlin (BI 907828) is an orally active E3 ubiquitin-protein ligase MDM-2 inhibitor, preventing MDM-2 from negatively regulating the tumor suppressor p53. Brigimadlin can be used for antineoplastic research [2] .
    Brigimadlin
  • HY-163083

    MDM-2/p53 Apoptosis Cancer
    JN122, a spiroindoline-containing molecule, is a MDM2 inhibitor. JN122 Inhibits MDM2/p53 protein–protein interaction and exerts robust in vivo antitumor efficacy. JN122 has antiproliferative activity in HCT-116 cells and HEK-293 cells with IC50 values of 39.6 nM and 4.28μM, respectively. JN122 can promote activation of p53 and its target genes, inhibited cell cycle progression, and induced cell apoptosis .
    JN122

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: